Estimating absolute risks in the presence of nonadherence: An application to a follow-up study with baseline randomization

Epidemiology

Volumn 21, Issue 4, 2010, Pages 528-539

  Toh, Sengwee ^a   Hernández Díaz, Sonia ^a   Logan, Roger ^a   Robins, James M ^a   Hernán, Miguel A ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO; ESTROGEN; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROBABILITY; RANDOMIZATION; RISK ASSESSMENT; TREATMENT REFUSAL; ADVERSE EFFECTS; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; CONFIDENCE INTERVAL; ESTROGEN THERAPY; KAPLAN MEIER METHOD; MEDICATION COMPLIANCE; MIDDLE AGED; MONTE CARLO METHOD; ODDS RATIO; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SELECTION BIAS; STATISTICS AND NUMERICAL DATA;

AGED; BREAST NEOPLASMS; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MEDICATION ADHERENCE; MEDROXYPROGESTERONE ACETATE; MIDDLE AGED; MONTE CARLO METHOD; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SELECTION BIAS; KAPLAN-MEIER ESTIMATE;

EID: 77953957776     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/EDE.0b013e3181df1b69     Document Type: Article

References (34)

1. Robins JM. Correction for non-compliance in equivalence trials. Stat Med. 1998;17:269-302; discussion 387-389.
2. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology. 2000;11:550-560.
3. Hernán MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology. 2000;11:561-570.
4. Toh S, Hernán MA. Causal inference from longitudinal studies with baseline randomization. Int J Biostat. 2008;4: Article 22. Available at: http://www.bepress.com/ijb/vol4/iss1/22.
5. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56:779-788.
6. Robins JM. The analysis of randomized and non-randomized AIDS treatment trials using a new approach to causal inference in longitudinal studies. In: Sechrest L, Freeman H, Mulley A, eds. Health Service Research Methodology: A Focus on AIDS. Washington, DC: NCHSR, US Public Health Service; 1989:113-159.
7. Robins JM. Analytic methods for estimating HIV treatment and cofactor effects. In: Ostrow DG, Kessler R, eds. Methodological Issues of AIDS Mental Health Research. New York: Plenum Publishing; 1993:213-290.
8. Robins JM, Hernán MA. Estimation of the causal effects of time-varying exposures. In: Fitzmaurice G, Davidian M, Verbeke G, et al, eds. Longitudinal Data Analysis. New York: Chapman and Hall/CRC Press; 2008:553-599
9. The Writing Group for the Women's Health Initiative Investigators.
10. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333
11. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19:61-109.
12. Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003;13(suppl 9):S122-S128.
13. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmeno-pausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003;289:3243-3253.
14. Anderson GL, Chlebowski RT, Rossouw JE, et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas. 2006;55:103-115.
15. Thompson WA Jr. On the treatment of grouped observations in life studies. Biometrics. 1977;33:463-470.
16. Cotter D, Zhang Y, Thamer M, Kaufman J, Hernan MA. The effect of epoetin dose on hematocrit. Kidney Int. 2008;73:347-353.
17. Toh S, Hernández-Díaz S, Logan R, Rossouw JE, Hernán MA. Coronary heart disease in postmenopausal recipients of estrogen plus progestin therapy: does the increased risk ever disappear? A randomized trial. Ann Intern Med. 2010;152:211-217.
18. Hernán MA, Robins JM. Estimating causal effects from epidemiological data. J Epidemiol Community Health. 2006;60:578-586.
19. Wasserman L. All of Nonparametric Statistics. New York: Springer; 2006.
20. Hernán MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology. 2008;19:766-779.
21. Hernán MA, Robins JM, García Rodríguez LA. Discussion of "Statistical issues arising in the Women's Health Initiative" by Prentice RL, Pettinger M, Andreson GL. Biometrics. 2005;61:922-930.
22. Cain LE, Cole SR. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. Stat Med. 2009;28:1725-1738.
23. Cole SR, Hernán MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75:45-49.
24. Hernán MA, Lanoy E, Costagliola D, Robins JM. Comparison of dynamic treatment regimes via inverse probability weighting. Basic Clin Pharmacol Toxicol. 2006;98:237-242.
25. Robins J, Orellana L, Rotnitzky A. Estimation and extrapolation of optimal treatment and testing strategies. Stat Med. 2008;27:4678-4721.
26. Chlebowski RT, Anderson G, Pettinger M, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med. 2008;168:370-377. (Pubitemid 351347128)
27. Mark SD, Robins JM. A method for the analysis of randomized trials with compliance information: an application to the Multiple Risk Factor Intervention Trial. Control Clin Trials. 1993;14:79-97.
28. Mark SD, Robins JM. Estimating the causal effect of smoking cessation in the presence of confounding factors using a rank preserving structural failure time model. Stat Med. 1993;12:1605-1628.
29. Korhonen PA, Laird NM, Palmgren J. Correcting for non-compliance in randomized trials: an application to the ATBC Study. Stat Med. 1999; 18:2879-2897.
30. Joffe MM. Administrative and artificial censoring in censored regression models. Stat Med. 2001;20:2287-2304.
31. Cole SR, Chu H. Effect of acyclovir on herpetic ocular recurrence using a structural nested model. Contemp Clin Trials. 2005;26:300-310.
32. Greenland S, Lanes S, Jara M. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estima-tion. Clin Trials. 2008;5:5-13.
33. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15:615-625.
34. Cole SR, Hernán MA. Constructing inverse probability weights for marginal structural models. Am J Epidemiol. 2008;168:656-664.